View Older Stories

Dec 26, 2025 07:01AM Agios Pharma (AGIO) PT Raised to $34 at BofA Securities

Dec 24, 2025 12:28PM Agios Pharma (AGIO) PT Raised to $62 at H.C. Wainwright

Dec 9, 2025 06:56AM H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Dec 8, 2025 07:02AM Agios awaits FDA decision on mitapivat for thalassemia treatment

Nov 25, 2025 07:31AM Agios Pharma (AGIO) Management Sees a Path to Profitability - Cantor Fitzgerald

Nov 25, 2025 07:09AM Citi Opens 30-Day Positive Catalyst Watch on Agios Pharma (AGIO)

Nov 25, 2025 06:59AM Citi Starts Agios Pharma (AGIO) at Buy, PT $38

Nov 24, 2025 07:36AM Truist Securities Starts Agios Pharma (AGIO) at Buy

Nov 20, 2025 07:51AM Agios Pharma's (AGIO) Regulatory Path in the Air - Cantor Fitzgerald

Nov 20, 2025 06:38AM Agios Pharma (AGIO) PT Lowered to $48 at H.C. Wainwright

Nov 20, 2025 06:19AM Leerink Partners Upgrades Agios Pharma (AGIO) to Outperform

Nov 19, 2025 03:04PM Agios Pharma (AGIO) call put ratio 1 call to 1.2 puts with a focus on January 22.50 puts and January 45 calls

Nov 19, 2025 01:53PM Agios Pharma (AGIO) PT Lowered to $32 at BofA Securities

Nov 19, 2025 12:44PM RBC Capital Downgrades Agios Pharma (AGIO) to Sector Perform

Oct 30, 2025 06:30AM Agios Pharma (AGIO) Tops Q3 EPS by 12c

Oct 20, 2025 06:42AM H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Oct 17, 2025 08:15AM CHMP recommends PYRUKYND approval for adults with thalassemia

Oct 17, 2025 08:01AM Agios' PYRUKYND receives positive European opinion for thalassemia

Oct 16, 2025 04:45AM Increasing unusual option volume: HOND TMQ UROY WWR TTI AGIO GTES

Sep 24, 2025 03:10PM SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Agios Pharmaceuticals, Inc. (AGIO) and Encourages Long-Term Investors to Contact the Firm

Sep 5, 2025 06:44AM H.C. Wainwright Reiterates Buy Rating on Agios Pharma (AGIO)

Sep 5, 2025 05:02AM Goldman Sachs on Agios Pharma (AGIO): 'we see a favorable risk-benefit profile'

Sep 4, 2025 12:08PM TD Cowen on Agios Pharma (AGIO): 'we view an extension rather than issuance of a CRL as a positive sign'

Sep 4, 2025 10:23AM Agios Pharma (AGIO) PT Lowered to $51 at BofA Securities

Sep 4, 2025 07:00AM FDA extends PYRUKYND review date to December for thalassemia treatment

Aug 5, 2025 09:07AM TD Cowen on Agios Pharma (AGIO): 'Per Usual FAERS Mislead; AGIO Remains Our Top Pick'

Aug 5, 2025 06:34AM Agios Pharma (AGIO) PT Raised to $52 at BofA Securities

Aug 4, 2025 04:01PM Agios' PYRUKYND approved for thalassemia treatment in Saudi Arabia

Aug 4, 2025 01:59PM Agios addresses analyst report on PYRUKYND safety data

Jul 31, 2025 06:31AM Agios Pharma (AGIO) Misses Q2 EPS by 12c

Jul 8, 2025 07:00AM Agios Pharmaceuticals adds Dr. Jay Backstrom to board of directors

Jun 16, 2025 09:36AM TD Cowen Names Agios Pharma (AGIO) 'Best Smidcap Idea'

Jun 10, 2025 06:37AM Agios Pharma (AGIO) PT Lowered to $56 at H.C. Wainwright

Jun 9, 2025 08:41AM Avanzanite Bioscience Announces Pan-European Partnership with Agios to Launch PYRUKYND in Rare Blood Disorders

May 25, 2025 03:00PM Biotech stocks Q1 earnings review

May 13, 2025 07:36AM Cantor Fitzgerald Reiterates Overweight Rating on Agios Pharma (AGIO)

May 2, 2025 07:12AM Agios Pharma (AGIO) PT Lowered to $71 at Scotiabank

May 1, 2025 06:31AM Agios Pharma (AGIO) Tops Q1 EPS by 23c

Apr 12, 2025 04:00AM Biotech sector Q1 earnings preview from RBC Capital Markets

Apr 2, 2025 07:04AM Smid cap biotech investors must stop chasing binary events says Cantor Fitzgerald

Mar 5, 2025 05:58PM Agios Pharma (AGIO) announces inducement grants to new CPO

Feb 24, 2025 06:21AM H.C. Wainwright Starts Agios Pharma (AGIO) at Buy

Feb 21, 2025 06:13AM Agios Pharma (AGIO) BofA Makes Changes to Endeavor List

Feb 13, 2025 06:32AM Agios Pharma (AGIO) reported revenue at $10.7 million

Feb 13, 2025 06:30AM Agios Pharma (AGIO) Reports Phase 3 ACTIVATE-Kids Study of Mitapivat Met Primary Endpoint

Jan 13, 2025 12:50PM RBC Capital Explores Biotech Implications Following Cavazzoni's Departure from the FDA

Jan 8, 2025 07:02AM Agios Pharma (AGIO) Announces FDA Acceptance of sNDA for PYRUKYND

Dec 21, 2024 10:00AM RBC report: Biotech faces both uncertainty and growth opportunities in 2025

Dec 18, 2024 07:04AM Agios Pharma (AGIO): European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios’ Mitapivat in Sickle Cell Disease

Dec 10, 2024 07:28AM Agios Pharma (AGIO) PT Raised to $57 at RBC Capital; 'We Are Continued Buyers'

View Older Stories